Qingchangzhili Decoction In The Treatment Of Mild And Moderate Ulcerative Colitis Large Intestine Clinical Research On Damp-Heat Syndrome

Objective:To observe the clinical efficacy of Qingchangzhili Decoction combined with mesalazine and positive drug mesalazine alone in the treatment of patients with mild to moderate UC and large intestine damp-heat type,and to provide clinical effective basis for further application of Qingchangzhili Decoction.Methods:A total of 60 patients with ulcerative colitis of mild to moderate severity and TCM syndrome differentiation of large intestine damp-heat type who were treated in Jiangsu Provincial Hospital of Traditional Chinese Medicine from January 2020 to December 2021 were collected and included in this clinical study.The 60 patients were divided into two groups.The treatment group was treated with Qingchangzhili Decoction combined with mesalazine;the control group was treated with conventional western medicine mesalazine for a total of 24 weeks of treatment,and colonoscopy reexamination was performed from 24 to 48 weeks.Observation indicators mainly include biological indicators,TCM symptom scores before and after treatment,modified Mayo score before and after treatment,multidimensional fatigue scale score before and after treatment,and adverse reactions after taking medicine.The treatment effects of the two groups were compared,mainly based on the difference of the modified Mayo score(the difference of the total Mayo score,the difference of the number of bowel movements,the difference of the blood in the stool,the difference of the score found under the endoscope,and the difference of the score of the doctor’s overall evaluation.value),the difference between the scores of each symptom of TCM and the difference in the total score,the evaluation standard for the efficacy of TCM symptoms,the difference between the scores of the multidimensional fatigue scale,and the comprehensive efficacy evaluation.Results:1.Modified Mayo score:The comparison results before and after treatment in the two groups showed that both treatment measures could reduce the frequency of defecation,improve blood in the stool,and improve intestinal mucosa,all P<0.05;The overall evaluation is better than the control group,P<0.05;there is no significant difference between the two groups in improving the frequency of defecation and blood in the stool,P>0.05.2.The efficacy score of traditional Chinese medicine symptoms:both patients responded to the two treatment measures,and the two groups improved the fever The effects in all aspects were not obvious,P>0.05;the effect of the experimental group on improving diarrhea,pus and bloody stool,and abdominal pain was more obvious than that of the control group,P<0.05.3.The clinical efficacy rate and endoscopic response rate of TCM symptom evaluation were better in the experimental group than the control group.group,P<0.05.4.There was no statistical difference between the experimental group and the control group in the clinical efficacy rate,clinical remission rate,mucosal healing rate,and multidimensional fatigue scale score in the comprehensive evaluation of western medicine,P>0.05.Conclusions:1.Qingchangzhili decoction combined with mesalazine in the treatment of patients with active mild to moderate ulcerative colitis can quickly and effectively induce clinical symptom relief.2.Qingchangzhili decoction combined with mesalazine has a significant effect in improving Mayo score compared with mesalazine alone.3.Qingchangzhili decoction combined with mesalazine can improve the clinical efficiency and endoscopic response rate of patients.